THE GREATEST GUIDE TO IWR-1

Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the primary-line therapy of CML-CP. 5 hundred and nineteen individuals with freshly diagnosed CML-CP have been randomly assigned to receive dasatinib in a dose of 100 mg once day-to-day (259 patients) or imatinib at a dose of four hundred mg when